Literature DB >> 17613428

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.

Alwin Krämer1, Andreas Reiter, Jens Kruth, Philipp Erben, Andreas Hochhaus, Martin Müller, Nicholas C P Cross, Amy V Jones, Anthony D Ho, Manfred Hensel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17613428     DOI： 10.1016/S1470-2045(07)70206-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  19 in total

1.  Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Authors:  Monika Ribeiro Mello de Conchon; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Pedro Enrique Dorlhiac-Llacer; Dalton de Alencar Fischer Chamone; Israel Bendit
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

2.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 3.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

4.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

5.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

7.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

8.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

Review 9.  Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Authors:  Yanhua Yue; Wei Wei; Yanting Guo; Fei Wang; Weimin Dong; Yue Liu; Yan Lin; Yang Cao; Weiying Gu
Journal:  Am J Case Rep       Date:  2020-10-06

10.  A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Authors:  Ping Chong Bee; G G Gan; V S Nadarajan; N A Latiff; N Menaka
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.